Drug Overview
Empliciti (elotuzumab; Bristol-Myers Squibb/AbbVie) is a monoclonal antibody that targets the signaling lymphocytic activation molecule family, member 7 (SLAMF7), also called CS1.
This cell-surface glycoprotein is expressed in high levels on multiple myeloma (MM) cells and normal plasma cells.
It is also expressed on natural killer (NK) cells where it functions as an activating receptor. Empliciti induces MM cell death by direct activation of NK cells and through antibody-dependent NK cell-mediated cytotoxicity.
Empliciti (elotuzumab; Bristol-Myers Squibb/AbbVie) is a monoclonal antibody that targets the signaling lymphocytic activation molecule family, member 7 (SLAMF7), also called CS1.
This cell-surface glycoprotein is expressed in high levels on multiple myeloma (MM) cells and normal plasma cells.
It is also expressed on natural killer (NK) cells where it functions as an activating receptor. Empliciti induces MM cell death by direct activation of NK cells and through antibody-dependent NK cell-mediated cytotoxicity.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
